Perspective Therapeutics (CATX) Research & Development (2010 - 2026)
Perspective Therapeutics (CATX) recorded Research & Development of $21.54 million in Q2 2026, up 29.6% from $16.62 million a year earlier and up 0.8% from the prior quarter.
Powered by 
Analysis
Perspective Therapeutics (CATX) Research & Development (2010 - 2026) Analysis & Trends
On a TTM basis, Perspective Therapeutics' Research & Development came in at $73.87 million as of Jun 30, 2026, up 32.2% year-over-year; for FY2025, it came in at $84.22 million, up 102.3% from FY2024.
- Annual Research & Development has a five-year compound annual growth rate of 137.0% (FY2020 to FY2025).
- Across earlier years, Research & Development came in at $41.64 million in FY2024 (+95.4%), $21.31 million in FY2023, $881,000 in FY2022 and $1.43 million in FY2021 (+26.7%).
- The Q2 2026 figure is the highest quarterly Research & Development in data going back to Q1 2023.
- The year-over-year growth in Research & Development has ranged between 29.6% (Q2 2026) and 125.2% (Q1 2024) over the last five years.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.62 Bn | 1,105.21 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 617.59 Bn | 536.12 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 501.69 Bn | 474.80 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 368.29 Bn | 322.67 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 297.79 Bn | 261.78 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 260.82 Bn | 234.50 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 236.53 Bn | 191.93 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 191.14 Bn | 165.33 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 169.69 Bn | 116.33 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Perspective Therapeutics | 276.89 Mn | 39.99 Mn | - | 21.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.54 Mn |
| Mar 31, 2026 | 21.37 Mn |
| Jun 30, 2025 | 16.62 Mn |
| Mar 31, 2025 | 14.33 Mn |
| Dec 31, 2024 | 12.88 Mn |
| Sep 30, 2024 | 12.03 Mn |
| Jun 30, 2024 | 9.28 Mn |
| Mar 31, 2024 | 7.45 Mn |
| Dec 31, 2023 | 7.08 Mn |
| Sep 30, 2023 | 5.55 Mn |
| Jun 30, 2023 | 5.37 Mn |
| Mar 31, 2023 | 3.31 Mn |
| Sep 30, 2022 | 708,000.00 |
| Jun 30, 2022 | 796,000.00 |
| Mar 31, 2022 | 549,000.00 |
| Dec 31, 2021 | 535,000.00 |
| Sep 30, 2021 | 702,000.00 |
| Jun 30, 2021 | 468,000.00 |
| Mar 31, 2021 | 362,000.00 |
| Dec 31, 2020 | 285,000.00 |
API Access
Perspective Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=CATX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "CATX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=CATX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();